Deal Watch: Roche Partners With Dyno On AAV-Delivered Gene Therapies
Also, deals between Boehringer Ingelheim/Oxford BioTherapeutics, Bausch/Eyenovia, Ligand/HitGen, Moderna/Merck & Co., Vincera/Bayer, Genentech/Kineta, Selecta/IGAN, RedHill/AstraZeneca, Urovant/Sunovion, Biogen/Scribe, BridgeBio/Eidos, Elevar/Taiba
You may also be interested in...
Positive Phase III topline results follow the US FDA’s acceptance of the drug in cholangiocarcinoma and encouraging data in low-grade glioma at ASCO 2021.
Several companies have recently raised large amounts of money from venture capital as well as potentially through partnerships for next-generation capsid technology.
Biogen is Capsigen’s first partner, while Dyno Therapeutics has also entered into deals potentially worth billions with large drug and biotech firms.